All individual trials at Shanghai YingLi Pharmaceutical Co. Ltd.

An AllTrials project

All individual trials at Shanghai YingLi Pharmaceutical Co. Ltd.

0 out of 2

0.0%

$231,380

$0

Status	Sponsor	Trial ID	Title	Completion date	Days overdue
overdue	Shanghai YingLi Pharmaceutical Co. Ltd.	NCT04379167	A Phase 2, Single Arm, Open Label Clinical Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of YY-20394 in Patients With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma Who Have Failed at Least Two Prior Systemic Therapies.	2022-12-30	41
overdue	Shanghai YingLi Pharmaceutical Co. Ltd.	NCT05274997	A Single-arm, Phase II Study to Evaluate the Efficacy and Safety of Linperlisib (YY-20394) Monotherapy in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma	2023-01-01	39
ongoing	Shanghai YingLi Pharmaceutical Co. Ltd.	NCT05119933	A Phase 1/2, Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation	2023-06-01

Download this data